



(12) Translation of
European patent specification

(11) NO/EP 3160948 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 265/36 (2006.01)
A61K 31/538 (2006.01)
A61P 9/12 (2006.01)

Norwegian Industrial Property Office


(21)	Translation Published	2019.04.01
(80)	Date of The European Patent Office Publication of the Granted Patent	2018.10.24
(86)	European Application Nr.	15736015.7
(86)	European Filing Date	2015.06.26
(87)	The European Application's Publication Date	2017.05.03
(30)	Priority	2014.06.30, US, 201462018790 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ME
(73)	Proprietor	Astrazeneca AB, 151 85 Södertälje, Sverige
(72)	Inventor	O'MAHONY, Gavin, AstraZenecaR&D Mölndal, SE-431 83 Mölndal, Sverige KOSSENJANS, Michael, AstraZenecaR&D Mölndal, SE-431 83 Mölndal, Sverige EDMAN, Karl, AstraZenecaR&D Mölndal, SE-431 83 Mölndal, Sverige KAJANUS, Johan, AstraZenecaR&D Mölndal, SE-431 83 Mölndal, Sverige HOGNER, Carl Anders, AstraZenecaR&D Mölndal, SE-431 83 Mölndal, Sverige CORNWALL, Philip, AstraZenecaCharter Way, MacclesfieldCheshire SK10 2NA, Storbritannia TURNER, Andrew, AstraZenecaCharter Way, MacclesfieldCheshire SK10 2NA, Storbritannia
(74)	Agent or Attorney	TANDBERG INNOVATION AS, Postboks 1570 Vika, 0118 OSLO, Norge

(54)	Title	BENZOXAZINONE AMIDES AS MINERALOCORTICOID RECEPTOR MODULATORS
(56)	References Cited:	HASUI TOMOAKI ET AL: "Design, synthesis, and structure-activity relationships of dihydrofuran-2-one and dihydropyrrol-2-one derivatives as novel benzoxazin-3-one-based mineralocorticoid receptor antagon", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 21, no. 19, 31 July 2013 (2013-07-31) , pages 5983-5994, XP028706278, ISSN: 0968-0896, DOI: 10.1016/J.BMC.2013.07.043, WO-A2-2006/015259

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Forbindelse med formel (I)



hvor

R¹ er valgt fra CONH₂ eller CONHCH₃; og

R² er valgt fra H, F, Cl eller Br;

eller et farmasøytisk akseptabelt salt derav.

2. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt derav, hvor

R¹ er CONHCH₃; og

R² er valgt fra H, F, Cl eller Br.

3. Forbindelse ifølge krav 1 eller et farmasøytisk akseptabelt salt derav, hvor

R¹ er CONHCH₃; og

R² er F.

4. Forbindelse ifølge krav 1, som er valgt fra

2-{4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

N-metyl-2-{4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

N-metyl-2-{(3S)-4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

N-metyl-2-{(3R)-4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

2-{7-fluor-4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

2-{(3S)-7-fluor-4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

2-{(3R)-7-fluor-4-[(3-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl)karbonyl]-3,4-dihydro-2H-1,4-benzoksazin-3-yl}acetamid;

- 2- $\{7\text{-fluor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 2- $\{(3S)\text{-7-fluor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 5 2- $\{(3R)\text{-7-fluor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 2- $\{7\text{-klor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ acetamid;
- 2- $\{(3S)\text{-7-klor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ acetamid;
- 10 2- $\{(3R)\text{-7-klor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ acetamid;
- 2- $\{7\text{-klor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 15 2- $\{(3S)\text{-7-klor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 2- $\{(3R)\text{-7-klor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 2- $\{7\text{-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ acetamid;
- 20 2- $\{(3S)\text{-7-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ acetamid;
- 2- $\{(3R)\text{-7-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ acetamid;
- 25 2- $\{7\text{-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 2- $\{(3S)\text{-7-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 2- $\{(3R)\text{-7-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- 30 2- $\{7\text{-brom-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid;
- eller et farmasøytisk akseptabelt salt derav.

5. Forbindelse ifølge krav 1, som er 2- $\{(3S)\text{-7-fluor-4-}[(3\text{-okso-3,4-dihydro-2H-1,4-benzoksazin-6-yl})\text{karbonyl}]\text{-3,4-dihydro-2H-1,4-benzoksazin-3-yl}\}$ -*N*-metylacetamid.

35

6. Farmasøytisk formulering som omfatter en forbindelse med formel (**I**) eller et farmasøytisk akseptabelt salt av en forbindelse med formel (**I**) ifølge et hvilket som helst av kravene 1 til 5 og en farmasøytisk akseptabel bærer, hjelpestoff eller

fortynningsmiddel.

7. Forbindelse med formel (**I**) eller et farmasøytisk akseptabelt salt av en forbindelse med formel (**I**) ifølge et hvilket som helst av kravene 1 til 5 for anvendelse i terapi.

5

8. Forbindelse med formel (**I**) eller et farmasøytisk akseptabelt salt av en forbindelse med formel (**I**) ifølge et hvilket som helst av kravene 1 til 5 for anvendelse ved behandling og/eller forebygging av kardiovaskulær sykdom.

10 **9.** Forbindelse for anvendelse ifølge krav 8; hvori den kardiovaskulære sykdommen er hjertesvikt.

10. Forbindelse med formel (**I**) eller et farmasøytisk akseptabelt salt av en forbindelse med formel (**I**) ifølge et hvilket som helst av kravene 1 til 5 for anvendelse ved

15 behandling og/eller forebygging av kronisk nyresykdom.